Development of a Novel Combination Therapy targeting
MET and LGR5 to overcome Colorectal Cancer Resistance
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INTRODUCTION

RESULTS

Therapy-induced resistance and recurrence contribute to a majority of the
challenges encountered in the clinical management of colorectal cancer
(CRC). The chief culprits behind colorectal tumor relapse are cancer stem
cells (CSCs). CSCs promote tumor progression and clonal heterogeneity
owing to their self-renewability, plasticity, and differentiation capacity. Upon
therapy termination, CSCs exit dormancy and circulate to secondary sites
where they spawn metastases leading to disease-induced mortality. Leucine
rich repeat-containing G protein-coupled receptor 5 (LGR5) is highly
expressed in CRC and is a bona fide marker of functional CSCs. LGR5+ CSCs
are often responsible for tumor initiation and metastatic outgrowth, however
their conversion into a chemo-resistant LGR5- state is vital for metastatic
dissemination. LGR5-targeted therapy results in tumor regression, yet LGR5tumors eventually relapse due to plasticity. Successful elimination of CRC
tumors can be achieved by targeting both LGR5+ CSCs and LGR5- CRC cell
populations. LGR5- CRC cells, at least in part, rely on the MET/STAT3
pathway to evade therapy. MET is a well-characterized oncogene
upregulated and associated with poor prognosis in many solid tumor types,
including CRC. For this project, we are generating MET-targeted antibodydrug conjugates (ADCs), which will act as guided missiles to deliver
cytotoxic agents to CRC cells expressing high levels of MET, including
therapy-resistant LGR5- CRC cells.

WORKING MODEL

Figure 2. (A) LGR5 and MET RNA-Seq RSEM values for
matched tumor and adjacent normal from the colorectal
adenocarcinoma (COADREAD) cohort of the Cancer
Genome Atlas (TCGA). (B) Kaplan Meier curves
comparing Disease-Free Survival with MET expression
status. (C) Comparison of MET and LGR5 RNA-Seq RSEM
values in CRC cell lines. (D) Immunoblotting of
endogenous MET and LGR5 expression in CRC cell lines.

Figure 3. (A) Western blot of changes in MET
and STAT3 in LoVo control and LGR5 KD
cells. (B) Western blot of changes in MET and
STAT3 in LS180 control and LGR5 CRISPR KO
cells. (C-D) Western blots of MET and STAT3
phosphorylation in (C) LoVo and (D) LS180
cells treated with anti-LGR5 ADC (6.5 nM) at
different time-points.

Figure 4. (A) Coomassie blue staining of c-MET monoclonal
antibodies (mAbs) MC8 and A700. (B) Immunocytochemistry validation of MC8 and A700 binding to
human c-MET and internalization into LAMP1+ lysosomes in
LoVo cells. (C) Fluorescence cell-based binding assay
confirming MC8 and A700 binding to DLD1 cells. (D)
Western Blot confirming downstream MET phosphorylation
inhibition by MC8. (E-F) Cytotoxicity of (E) MC8 and (F)
A700 coincubated with PBD-conjugated secondary mAbs.

DISCUSSION
●
●
●

In addition to c-MET overexpression in a majority of CRC patients, it's downstream activation upon LGR5 loss makes c-MET a promising therapeutic target.
Both ABT-700 and MC8 c-MET mAbs demonstrates high binding affinity, internalization and lysosomal colocalization in human colorectal cancer cells
Ongoing studies include conjugation with different cytotoxic payloads and validation in a wider panel of CRC cell lines and patient derived xenografts.
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